To Evaluation of Effectiveness of Chelatory Therapy in Patients with Talassemia

Zaynutdinova D.L., Qudratova M.F., Qo’ziyeva M.G., Muhammadaminova D.R., Axtamov A.J.

dc.contributor.author	Zaynutdinova D.L., Qudratova M.F., Qo’ziyeva M.G., Muhammadaminova D.R., Axtamov A.J.
dc.date.accessioned	2023-01-10T07:36:41Z
dc.date.available	2023-01-10T07:36:41Z
dc.date.issued	2022
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/5730
dc.description.abstract	The term “thalassemia” refers to a group of autosomal-recessive blood diseases charaeterized by a decrease in the synthesis of one of two types of polypeptide chains of globin (α or β), that form a molecule of adult hemoglobin(HbA, α2β2). This leads to a decrease in the filling of erythrocytes with hemoglobin and anemia. In Uzbekistan, the birth rate with this disease is 10-15 per year. At present in the Republic of Uzbekistan, 184 patients with thalassemia are registered at the Research Institute of Hematology and Blood Transfuzion at the Dispensary	en_US
dc.language.iso	en_US	en_US
dc.publisher	USA	en_US
dc.relation.ispartofseries	УДК;
dc.subject	anemia, hemoglobinopathy, thalassemia, hemosiderosis	en_US
dc.title	To Evaluation of Effectiveness of Chelatory Therapy in Patients with Talassemia	en_US
dc.type	Article	en_US